Kiniksa Pharmaceuticals International (KNSA) TD Cowen 46th Annual Health Care Conference summary

Key growth drivers and commercial performance

• Achieved $677.6 million cumulative net revenue in 2025, representing 62% year-over-year growth.

• Growth driven by increased patient adds, more prescribers, higher repeat prescribing, and longer therapy duration.

• Average treatment duration is approaching three years, aligning with the chronic nature of the disease.

• Guidance for 2026 is $920 million in cumulative net revenue, reflecting continued expansion.

• Only 18% penetration in the multiple recurrence market, with significant opportunity remaining.

Market penetration and prescriber strategy

• Over 4,150 unique prescribers reached, with a target market of 20,000–30,000 prescribers.

• Dual strategy focuses on expanding both breadth (new prescribers) and depth (repeat prescribing).

• AI, digital marketing, and medical education are key tools for increasing adoption.

• Recent clinical guidance supports use after NSAIDs and colchicine, before corticosteroids.

• 20% of enrollments now come from first recurrence patients, indicating growing early adoption.

Pipeline and future development

• Phase II data for KPL-387 expected in the second half of the year, with a focus on monthly dosing and potential auto-injector use.

• Phase III initiation planned as soon as possible after Phase II, leveraging existing clinical relationships.

• KPL-1161 is in preclinical development with every three-month dosing; indication not yet disclosed.

• Ongoing evaluation of ex-U.S. opportunities, with a global mindset but current focus on U.S. market.

• Cash flow will support pipeline expansion and potential business development, with high standards for new assets.